Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

Delayed Quote. Delayed  - 06/24 10:00:04 pm
229.02 USD   -4.02%
06/21 BIOGEN : Names Paul McKenzie Executive Vice President, Pharmaceutica..
06/20 BIOGEN : to Report Second Quarter 2016 Financial Results on July 21,..
06/09 BIOGEN : New Data Presented at the Annual European Congress of Rheum..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/20/2013 | 01:06pm CEST
   By Saabira Chaudhuri 
 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on BIOGEN INC
06/21 BIOGEN INC. : Change in Directors or Principal Officers (form 8-K)
06/21 BIOGEN : Names Paul McKenzie Executive Vice President, Pharmaceutical Operations..
06/20 BIOGEN : to Report Second Quarter 2016 Financial Results on July 21, 2016
06/09 BIOGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/09 BIOGEN : New Data Presented at the Annual European Congress of Rheumatology (EUL..
06/08DJBIOGEN : MS Drug Fails Study Goals; Shares Drop 13% -- WSJ
06/07DJBIOGEN : Shares Down as Multiple Sclerosis Therapy Misses Study Goals -- Update
06/07DJBiogen Shares Down as Multiple Sclerosis Therapy Misses Study Goals
06/07DJBIOGEN : Shares Down as Multiple Sclerosis Therapy Misses Study Goals
06/07 BIOGEN : Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials